Umang Gunvantray Thakkar

Scopus Publications

A new report under the spotlight: FATCO syndrome phenotype with an absent uvula and acyanotic congenital heart diseases in an Indian female newborn: Variant of FATCO syndrome
U.G. Thakkar, K.M. Shah, Z.Z. Raja, R.S. Aggarwal, R.D. Patel, L.A. Nigam
Journal of Neonatal Nursing, 2024
Thrombotic microangiopathy in a renal allograft: Single-center five-year experience
ArunaV Vanikar, KamalV Kanodia, KamleshS Suthar, LoveleshA Nigam, RashmiD Patel, UmangG Thakkar, AanalH Mehta
Saudi Journal of Kidney Diseases and Transplantation, 2020
Thrombotic microangiopathy (TMA) is devastating for renal transplantation (RT) causing graft/ patient loss. We present 5-year experience of TMA in RT in retrospective study of indicated renal allograft biopsies with TMA. Patient-donor demographics and associated histological findings with respect to transplants under tolerance induction protocol (Group 1) were compared with patients transplanted under triple immunosuppression (Group 2). Statistical analysis was performed using IBM SPSS Statistics version 20. Sixty-one (4.1%) of 1520 biopsies [Group 1:17 (1.9%)/882, Group 2:44 (6.9%)/638] revealed TMA. Tacrolimus trough levels were normal. There was no evidence of systemic involvement in any patient. Mean age was 36.8 years with 70.6% males, HLA-match, 2.6/6, and the most common original disease unknown (41.2%) in Group 1, and 35.9 years with 86.4% males, HLA-match, 2.1/6, and the most common original disease unknown (50%) in Group 2. Biopsies were performed at mean 5.1-year posttransplant in Group 1 and 2.3 years in Group 2. Acute TMA constituted 47% Group 1 and 43.2% Group 2 biopsies; of these, antibody-mediated rejections were observed in 58.8%, T-cell mediated rejections in 11.8%, tacrolimus toxicity in 76.5%, and other findings in 35.3% Group 1; and 61.4%, 25%, 50%, and 18.2%, respectively, in Group 2 biopsies. Higher rejection activity scores were more in Group 2. Postbiopsy 1- and 5- year patient survival was 94.1%, 86.9% in Group 1 and 92.1%, 88.3% in Group 2; 1- and 4-year graft survival was 52.9%, 15.9% in Group 1 and 20.3%, 5.4% in Group 2. TMA was poor prognosticator for RT, especially under triple immunosuppression. Antibody- mediated rejection and tacrolimus toxicity were more prone to TMA.
Bone mineral changes after renal transplantation
Kuwait Medical Journal, 2019
Urinary Screening for Early Detection of Kidney Diseases
Kamlesh S. Suthar, Aruna V. Vanikar, Lovelesh A. Nigam, Rashmi D. Patel, Kamal V. Kanodia, Umang G. Thakkar, Paulin A. Gandhi, Sheetal A. Chandak, Amit V Prajapati, Minaxi H. Patel
Indian Journal of Pediatrics, 2018
Newborn with absent thumb and imperforate anus in absence of familial context- Is it Holt-Oram syndrome?
U.G. Thakkar, A.V. Vanikar, V.V. Mishra, D.R. Singh, H.L. Trivedi, S.R. Lamba, S.A. Hokaboj, V.J. Desai
Journal of Neonatal Nursing, 2018
Six years’ experience of tolerance induction in renal transplantation using stem cell therapy
Aruna V. Vanikar, Hargovind L. Trivedi, Umang G. Thakkar
Clinical Immunology, 2018
Congenital venous malformation in an 8-year-old female child treated with ethanol injection
Puerto Rico Health Sciences Journal, 2017
Repercussions of eosinophils in a renal allograft - Predictor of early graft loss!
ArunaV Vanikar, KamalV Kanodia, RashmiD Patel, KamleshS Suthar, LoveleshA Nigam, UmangG Thakkar, HimanshuV Patel, VivekB Kute, HargovindL Trivedi
Saudi Journal of Kidney Diseases and Transplantation an Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia, 2017
We present 5-year experience of renal transplantation (RT) with tissue eosinophilia (TE) in renal allograft biopsy (RAB) and its repercussions on the outcome. In total, 1217 recipients underwent RT from 2011 to 2015, and they were evaluated for the presence of ≥4% TE. Group 1 consisted of RT with RAB showing TE, Group 2 consisted of RT with RAB with rejections without TE, and Group 3 consisted of RT without rejections. Group 1 had 27 recipients, Group 2 had 395, and Group 3 had 795 recipients. The outcome in terms of graft function, patient and graft survival were evaluated and compared between three groups. All recipients received standard triple immunosuppression. One-year patient and death-censored graft survival were 80.7% and 82.7% in Group 1, 87.2% and 95.1% in Group 2, and 92.6% and 99.6%, respectively in Group 3 and corresponding mean serum creatinine (SCr, mg/dL) was 1.60 ± 0.45 in Group 1, 1.63 ± 0.58 in Group 2, and 1.19 ± 0.39 Group three, respectively. Five-year patient and death-censored graft survival were 72.9 % and 71.1% for Group 2 and 87% and 98.2% for Group 3 with SCr of 1.63 ± 0.38 and 1.25 ± 0.4, respectively. Group 1 recipients did not appear at five years. At four years posttransplant, patient and death-censored graft survival were 71.7% and 59.5% in Group 1 with SCr of 1.55 ± 0.65 mg/dL. In conclusion, the presence of eosino-phils in a renal allograft is an impending sign of graft damage and eventual graft loss.
Stem cells: An emerging novel therapeutic for type-1 diabetes mellitus
Umang G. Thakkar, Aruna V. Vanikar, Hargovind L. Trivedi
Diabetes Research and Clinical Practice, 2017
Revisit of a rare complication of type 1 diabetes mellitus: Mauriac syndrome
Umang G Thakkar, Aruna V Vanikar, Hargovind L Trivedi
Practical Diabetes, 2017
Mauriac syndrome is an uncommon complication of poorly‐controlled type 1 diabetes mellitus (T1DM) reported in children 13–17 years of age. It manifests as delayed growth, hepatomegaly, elevated liver enzymes and serum lipids, and glycogen accumulation in hepatocytes. Common presenting features include short stature, growth retardation, moon facies, protuberant abdomen and proximal muscle wasting. Since the advent of long‐ and intermediate‐acting insulin, this syndrome is now rarely encountered.We report the case of a 16‐year‐old male who had a 13‐year history of T1DM and was diagnosed with Mauriac syndrome. He was treated with biphasic isophane insulin and recovered – good glycaemic control was maintained, his height increased from 128cm to 141.5cm, hepatomegaly disappeared with normal liver enzymes, and the onset of pubertal spurt at eight months' follow up was shown.In conclusion, ensuring compliance with insulin therapy, and providing supportive treatment, nutritional support and good follow‐up care can help to mitigate most of the complications relating to Mauriac syndrome. Copyright © 2017 John Wiley & Sons.
Should we practice stem cell therapy for type 1 diabetes mellitus as precision medicine?
Umang G. Thakkar, Aruna V. Vanikar, Hargovind L. Trivedi
Cytotherapy, 2017
In vitro generated mesenchymal stem cells: Suitable tools to target insulin dependent diabetes mellitus?
Shruti D. Dave, Chetan N. Patel, Jignesh Patel, Umang G. Thakkar
Current Stem Cell Research and Therapy, 2017
Stem cell therapy: An emerging modality in glomerular diseases
Umang G. Thakkar, Aruna V. Vanikar, Hargovind L. Trivedi
Cytotherapy, 2017
Association of capillary haemangioma with bilateral hydronephrosis in an infant
Umang G Thakkar, Aruna V Vanikar, Hargovind L Trivedi, Kalpana S Vora, Yusuf Saifee
Sri Lanka Journalof Child Health, 2017
Co-infusion of insulin-secreting adipose tissue-derived mesenchymal stem cells and hematopoietic stem cells: novel approach to management of type 1 diabetes mellitus
U. G. Thakkar, H. L. Trivedi, A. V. Vanikar, S. D. Dave
International Journal of Diabetes in Developing Countries, 2016
Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus
Aruna V. Vanikar, Hargovind L. Trivedi, Umang G. Thakkar
Cytotherapy, 2016
High prevalence of chronic kidney disease in a semi-urban population of Western India
Hargovind Trivedi, Aruna Vanikar, Himanshu Patel, Kamal Kanodia, Vivek Kute, Lovelesh Nigam, Kamlesh Suthar, Umang Thakkar, Harsh Sutariya, Shruti Gandhi
Clinical Kidney Journal, 2016
Treating type-1 diabetes mellitus with insulin-secreting mesenchymal stem cells and haematopoietic stem cells followed by T-regulatory cells
Umang G Thakkar, Hargovind L Trivedi, Aruna V Vanikar
Sri Lanka Journalof Child Health, 2016
Anaphylactoid purpura manifested after acute gastroenteritis with severe dehydration in an 8-year-old male child: A case report
Puerto Rico Health Sciences Journal, 2015
Rare case of non-parasitic chyluria in pediatric population treated with dietary modification in a four-year-old male child
Kuwait Medical Journal, 2015
Novel therapy for insulin-dependent diabetes mellitus: infusion of in vitro-generated insulin-secreting cells
S. D. Dave, A. V. Vanikar, H. L. Trivedi, U. G. Thakkar, S. C. Gopal, T. Chandra
Clinical and Experimental Medicine, 2015
Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus
Umang G. Thakkar, Hargovind L. Trivedi, Aruna V. Vanikar, Shruti D. Dave
Cytotherapy, 2015
Fracture of shaft of left femur in a newborn delivered by caesarean section
U G Thakkar, V V Mishra, A V Vanikar, R S Agrawal, P G Kadam
Sri Lanka Journalof Child Health, 2015
Co-infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and bone marrow derived hematopoietic stem cells, a viable therapy for post-traumatic brachial plexus injury: A case report
HargovindL. Trivedi, UmangG. Thakkar, ArunaV. Vanikar
Biomedical Journal, 2014
Treatment of a Type-1 diabetic adolescent male with mitral valve prolapse with his mother's insulin secreting adipose tissue derived mesenchymal stem cells and bone marrow derived haematopoietic stem cells
Umang G Thakkar, Aruna V Vanikar, Hargovind L Trivedi, Shruti D Dave
Sri Lanka Journalof Child Health, 2014
Assessment of children born to mothers who are renal allograft recipients
U G Thakkar, V V Mishra, AV Vanikar, H V Patel, R S Agrawal, VR Shah, H L Trivedi
Sri Lanka Journalof Child Health, 2014
Co-infusion of autologous adipose tissue derived insulin-secreting mesenchymal stem cells and bone marrow derived hematopoietic stem cells: Viable therapy for type III C. a diabetes mellitus
UmangG Thakkar, ArunaV Vanikar, HargovindL Trivedi
Biomedical Journal, 2013
Down syndrome with end-stage renal disease
Vivek B. Kute, Aruna V. Vanikar, Pankaj R. Shah, Manoj R. Gumber, Himanshu V. Patel, Divyesh P. Engineer, Umang G. Thakkar, Hargovind L. Trivedi
Indian Journal of Clinical Biochemistry, 2013
Alkaptonuria in 17-month-old female child: A case report
Kuwait Medical Journal, 2013
Polyglandular autoimmune syndrome type III: Two cases
Umang G Thakkar, Aruna V Vanikar, Hargovind L Trivedi
Sri Lanka Journalof Child Health, 2013
Treatment of polyglandular autoimmune syndrome type 3 using co-transplantation of insulin-secreting mesenchymal stem cells and haematopoietic stem cells
Hargovind L Trivedi, Umang G Thakkar, Aruna V Vanikar, Shruti D Dave
BMJ Case Reports, 2011
Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: A novel therapy for insulin-dependent diabetes mellitus
A. V. Vanikar, S. D. Dave, U. G. Thakkar, H. L. Trivedi
Stem Cells International, 2010
Subarachnoid Placement of Stem Cells in Neurological Disorders
T. Mehta, A. Feroz, U. Thakkar, A. Vanikar, V. Shah, H. Trivedi
Transplantation Proceedings, 2008

Umang Gunvantray Thakkar

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications